PremiumThe FlyHikma Pharmaceuticals announces Health Canada approval of KLOXXADO nasal spray Emergent BioSolutions announces $27M in incremental sales Emergent BioSolutions reinforces commitment to expanding access to NARCAN PremiumThe FlyTarget reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz Emergent BioSolutions falls -24.6% Emergent BioSolutions falls -16.0% PremiumThe FlyEmergent BioSolutions sees Q1 revenue $200M-$240M, consensus $279M Emergent BioSolutions reports Q4 adjusted EPS 5c, consensus (50c) Emergent BioSolutions sees FY25 revenue $750M-$850M, consensus $1.13B